MedPath

Peramivir

Generic Name
Peramivir
Brand Names
Rapivab
Drug Type
Small Molecule
Chemical Formula
C15H28N4O4
CAS Number
330600-85-6
Unique Ingredient Identifier
9ZS94HQO3B
Background

Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days.

Indication

Peramivir is indicated for the treatment of acute uncomplicated influenza in patients six months and older who have been symptomatic for no more than two days.

Associated Conditions
Acute, uncomplicated Influenza
Associated Therapies
-

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

BioCryst Pharmaceuticals projects ORLADEYO net revenue between $515-$535M and total revenue (including RAPIVAB) between $540-$560M in 2025. Achieved operating profit in 2024, expects quarterly EPS profitability in 2H 2025. Plans new drug application for ORLADEYO granules for children under 12 and advances pipeline for Netherton syndrome and diabetic macular edema.

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Dr. Anil Diwan highlights the threat of rapidly evolving RNA viruses like H5N1, COVID-19, RSV, and hMPV, which can develop resistance to current treatments. NV-387, a broad-spectrum antiviral drug by NanoViricides, shows promise against these viruses by mimicking host features viruses need to infect, making viral escape unlikely. It has shown superior efficacy in animal models compared to existing treatments, positioning it as a potential game-changer in pandemic preparedness.
stocktitan.net
·

Antiviral Drug NV-387 Advances to Phase II Trials Amid Funding Needs

NanoViricides reported Q3 2024 financials with $3.87M cash and $7.36M net property assets. Lead drug NV-387, a broad-spectrum antiviral, is advancing to Phase II trials for MPOX, RSV, Influenza, and COVID. A Phase Ia/Ib trial was completed with no adverse events. The company raised $1.71M through an ATM offering and has a $3M credit line, but additional funding is needed for planned Phase II trials. NV-387 showed promising results in animal trials, potentially offering superior effectiveness over existing treatments.
© Copyright 2025. All Rights Reserved by MedPath